{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Folate+Receptor+Alpha+Positive", "query": { "condition": "Folate Receptor Alpha Positive" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Folate+Receptor+Alpha+Positive&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:36:47.976Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01689766", "title": "Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Technetium Tc 99m EC20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01689766" }, { "nct_id": "NCT03552471", "title": "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Folate Receptor Alpha Positive", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Uterine Serous Carcinoma", "Recurrent Uterine Carcinosarcoma", "Platinum Resistant Ovarian Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Rucaparib Camsylate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2018-07-12", "completion_date": "2022-12-19", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552471" }, { "nct_id": "NCT02317705", "title": "Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "OTL38", "type": "DRUG" }, { "name": "Near infrared camera imaging system", "type": "DEVICE" }, { "name": "Laparotomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "On Target Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2014-12", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 4, "location_summary": "Orange, California • Tampa, Florida • Rochester, Minnesota + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02317705" }, { "nct_id": "NCT04606914", "title": "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "mirvetuximab soravtansine (MIRV; IMGN853)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2021-05-27", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Oxford", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT04606914" }, { "nct_id": "NCT05456685", "title": "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 125, "start_date": "2022-09-28", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 35, "location_summary": "Tucson, Arizona • Fresno, California • Fullerton, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05456685" }, { "nct_id": "NCT02629549", "title": "Intraoperative Imaging of Pituitary Adenomas by OTL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Pituitary Neoplasms" ], "interventions": [ { "name": "OTL38", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2015-10", "completion_date": "2018-08-03", "has_results": false, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02629549" }, { "nct_id": "NCT03106077", "title": "Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "Folate Receptor Alpha Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2017-06-05", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2020-12-02", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03106077" }, { "nct_id": "NCT04241315", "title": "ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasms", "Lung Cancer" ], "interventions": [ { "name": "OTL38 for Injection", "type": "DRUG" }, { "name": "Near infrared camera imaging system", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "On Target Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2020-03-26", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2023-03-23", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 12, "location_summary": "Stamford, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 8 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04241315" }, { "nct_id": "NCT02872701", "title": "OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Neoplasms", "Lung Cancer" ], "interventions": [ { "name": "OTL38 for Injection", "type": "DRUG" }, { "name": "Near infrared camera imaging system", "type": "DEVICE" }, { "name": "Endoscopic or Thoracic Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "On Target Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 100, "start_date": "2017-05-04", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872701" }, { "nct_id": "NCT06365853", "title": "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Ovarian Cancer", "Folate Receptor-Alpha Positive" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "DRUG" }, { "name": "Lubricating Eye Drops", "type": "DRUG" }, { "name": "Prednisolone acetate ophthalmic suspension 1% eye drops", "type": "DRUG" }, { "name": "Brimonidine tartrate ophthalmic solution eye drops", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2024-07-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-05-22T05:36:47.976Z", "location_count": 12, "location_summary": "Los Angeles, California • Louisville, Kentucky • Silver Spring, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06365853" } ] }